Skip to Main Content

Advertisement

Issue Archive

Table of Contents

CLINICAL TRIALS AND OBSERVATIONS

The introduction of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib revolutionized the treatment of chronic lymphocytic leukemia. However, because inefficacy or intolerable side effects, some patients do not benefit. Acalabrutinib is a covalent BTK inhibitor with greater selectivity than ibrutinib. Byrd and colleagues explored acalabrutinib in patients refractory to or intolerant of ibrutinib, finding exciting evidence for efficacy and tolerability.

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

PLATELETS AND THROMBOPOIESIS

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

  • Cover Image

    Cover Image

    issue cover

    COVER FIGURE
    Definitive involved-site radiation therapy administered for stage IA nodular lymphocyte-predominant Hodgkin lymphoma of the right side of the neck. Lt, left; Rt, right. See the article by Pinnix et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal

Advertisement

X